Skip to main content

Table 2 Procedural characteristics and angiographic outcomes

From: Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial

Lesion-level characteristics

Sirolimus- and probucol-eluting stent (n = 849)

Zotarolimus-eluting stent (n = 439)

P value

Balloon diameter (mm)

3.05 (2.59–3.47)

3.02 (2.60–3.45)

0.82

Stented length (mm)

25 (18–34)

24 (18–33)

0.23

In stent analysis

Post-procedural minimal luminal diameter (mm)

2.50 ± 0.50

2.57 ± 0.49

0.045

Post-procedural percent diameter stenosis (%)

12 ± 7

11 ± 7

0.03

At follow-up minimal luminal diameter (mm)a

2.13 ± 0.73

2.20 ± 0.72

0.18

At follow-up percent diameter stenosis (%)a

24 ± 22

23 ± 21

0.68

Late lumen loss (mm)a

0.36 ± 0.63

0.36 ± 0.59

0.48

In segment analysis

Post-procedural minimal luminal diameter (mm)

2.23 ± 0.58

2.26 ± 0.55

0.33

Post-procedural percent diameter stenosis (%)

22 ± 12

22 ± 12

0.83

At follow-up minimal luminal diameter (mm)a

1.90 ± 0.70

1.98 ± 0.69

0.10

At follow-up percent diameter stenosis (%)a

33 ± 20

32 ± 19

0.20

Late lumen loss (mm)a

0.31 ± 0.61

0.26 ± 0.57

0.34

Binary restenosisa

107 (17.0)

57 (17.2)

0.95

  1. Data shown as mean ± SD or median (25th–75th percentiles) or n (%)
  2. aData available for 961 lesions (74.6 %)